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OBJECTIVES The main objective of the present study was to determine whether low physiological levels of
estrogen directly protect cardiac cells against metabolic stress.
BACKGROUND The beneficial effect of estrogens on the cardiovascular system has been traditionally ascribed
to decrease in peripheral vascular resistance and to an antiatherogenic action. Whether
physiological concentrations of 17b-estradiol (E2) are also able to protect cardiomyocytes
against metabolic insult directly is unknown.
METHODS Isolated ventricular cardiomyocytes were loaded with the Ca21-sensitive fluorescent dye
Fluo-3 and imaged by a digital epifluorescence imaging system. In cardiac cells preincubated
with hormones and/or drugs for 8 h, metabolic stress was induced by addition and removal
of 2,4-dinitrophenol (DNP).
RESULTS In cardiomyocytes, a 3-min-long exposure to chemical hypoxia, followed by reoxygenation,
produced intracellular Ca21 loading independently of gender (female: 729 6 88 nmol/liter;
male: 778 6 97 nmol/liter). Pretreatment with E2 (10 nmol/liter) significantly reduced the
magnitude of hypoxia/reoxygenation-induced Ca21 loading in female (E2-treated: 298 6 39
nmol/liter; untreated: 729 6 88 nmol/liter), but not in male (E2-treated: 1029 6 177
nmol/liter; untreated: 778 6 97 nmol/liter) cardiac cells. The protective action of E2 was not
mimicked by the inactive estrogen stereoisomer, 10 nmol/liter 17a estradiol (17a estradiol-
treated: 886 6 122 nmol/liter; untreated: 729 6 88 nmol/liter), and was abolished by
tamoxifen (1 mmol/liter), which acts as an antagonist of E2 on estrogen receptors (E2 plus
tamoxifen-treated: 702 6 98 nmol/liter; untreated: 729 6 88 nmol/liter).
CONCLUSIONS In a gender-dependent manner, E2 directly protects cardiac cells against hypoxia-
reoxygenation injury through an estrogen receptor–mediated mechanism. Such property of
E2 may contribute to cardioprotection in the female gender. (J Am Coll Cardiol 2000;36:
948–52) © 2000 by the American College of Cardiology
Gender-specific differences in the incidence of cardiovascu-
lar disease were recognized half a century ago. While the
risk of heart disease in men increases constantly with age,
premenopausal women have a significantly lower risk,
which, however, increases rapidly after menopause to levels
comparable to male counterparts (1). Estrogen substitution
in postmenopausal women reduces cardiovascular mortality
by 30% to 50%, suggesting that estrogens are protective (2).
In fact, the antiatherogenic action of estrogens on the lipid
profile and arterial wall has been well documented (3). More
recently, however, experiments performed in whole heart
preparations have revealed that estrogens may also decrease
infarct size and protect against ischemia-reperfusion injury
without changing hemodynamic parameters (4–7). These
findings have implied that estrogens can directly interact
with cardiomyocytes. This is supported by the finding that
17b-estradiol (E2), applied in high pharmacological con-
centrations, inhibits hyperkalemia-induced Ca21 loading in
cardiomyocytes through a “Ca21 antagonistic action” (8).
However, whether low physiological concentrations of E2
protect cardiomyocytes against metabolic insult is unknown.
We report that E2 protects cardiomyocytes against hypoxia-
reoxygenation, and we present evidence that gender plays a
crucial role in the cytoprotective action of estrogens.
METHODS
Single ventricular cardiomyocytes. Ventricular cardiomy-
ocytes were enzymatically dissociated from pentobarbital-
anesthetized, sexually mature female and male guinea pigs
(8,9). Hearts were perfused (at 37°C) with medium 199,
Ca21-EGTA-buffered low-Ca21 medium, and low-Ca21
medium containing pronase E (8 mg per 100 ml), protein-
ase K (1.7 mg per 100 ml), bovine albumin (0.1 g per 100
ml), and 200 mmol/liter CaCl2. Ventricles were cut into
fragments, and single cells were isolated by stirring tissue in
pronase E, proteinase K and collagenase (5 mg per 10 ml).
The investigation conformed with the “Guide for the Care
and Use of Laboratory Animals” (NIH publication 85-23,
revised 1985).
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Digital epifluorescent imaging. Rod-shaped cardiomyo-
cytes with clear striations and smooth surface were imaged
by digital epifluoresecent microscopy (8,9). Cells were
loaded (for 30 min) with the esterified form of the Ca21-
sensitive fluorescent probe Fluo-3 acethoxymethyl ester
(5 mmol/liter Fluo-3, dissolved in dimethyl sulfoxide plus
pluronic acid; Molecular Probes) and superfused with Ty-
rode solution (in mmol/liter: 136.5 NaCl; 5.4 KCl;
1.8 CaCl2; 0.53 MgCl2; 5.5 glucose; 5.5 HEPES-NaOH;
pH 7.4). Cardiomyocytes were imaged using a digital
epifluorescence imaging system coupled to an inverted
microscope (Zeiss Axiovert-135 TV) with a 340 oil-
immersion objective lens. A 100-W mercury lamp served as
a source of light to excite Fluo-3 at 488 nm. An excitation
dichroic mirror with a cutoff of 510 nm, and a long pass
emission filter with a cutoff of 520 nm, were used to detect
Fluo-3 fluorescence using an intensified charge coupled
device camera. Fluorescence was digitized using an imaging
software (Attoflor RatioVision, Atto Instruments). An es-
timate of cytosolic Ca21 concentration was calculated ac-
cording to the equation: [Ca21] 5 Kd(F 2 Fmin/Fmax 2 F),
where Fmin and Fmax are minimal and maximal fluorescence
intensity, Kd dissociation constant of the Fluo-3-Ca
21
complex (422 nmol/liter) and F intensity of fluorescence. To
obtain Fmin and Fmax values, cells were exposed to 100
mmol/liter ionomycin either in the absence of Ca21 (extra-
cellular Ca21 was removed and 3 mmol/liter EGTA added
to the extracellular solution) or in the presence of saturating
concentrations of Ca21 (10 mmol/liter CaCl2), respectively
(8,9).
Chemical hypoxia-reoxygenation injury. Cardiomyo-
cytes, superfused with Tyrode solution, were exposed to
2 mmol/liter 2,4-dinitrophenol (DNP), a metabolic poison
that inhibits mitochondrial oxidative phosphorylation. Fol-
lowing 3-min treatment, DNP was removed (;10 s was
required for removal of DNP), and cells reexposed to
Tyrode solution (9–11). We have previously established
that this protocol induces Ca21 overload in cardiomyocytes
followed by an irreversible cellular hypercontracture and cell
death, with the intracellular concentration of Ca21 reflect-
ing accurately the condition of a cardiac cell (9). Such
chemical hypoxia-reoxygenation protocol was applied to
cells previously incubated for 8 h in the absence (control) or
presence of E2 with or without the antiestrogen tamoxifen,
or in the presence of 17a-estradiol, an inactive E2 stereo-
isomer. Estrogens and tamoxifen were dissolved in alcohol,
and Fluo-3AM was dissolved in dimethyl sulfoxide plus
pluronic acid. The final concentration of solvents was kept
to less than 0.1%. At this concentration, solvents did not
affect intracellular Ca21 levels (8).
Statistical analysis. Data are presented as mean 6 SEM,
with n representing number of imaged fields. Mean values
were compared by the two-way repeated measures analysis
of variance (ANOVA) using SigmaStat program (Jandel
Scientific). A p value ,0.05 was considered statistically
significant.
RESULTS
Hypoxia-reoxygenation induces Ca21 loading in both
female and male cardiomyocytes. Resting cardiomyocytes
from both male and female hearts had a low cytosolic Ca21
concentration (98 6 11 nmol/liter; n 5 13–14; Fig. 1). A
3-min-long exposure to chemical hypoxia induced by the
mitochondrial uncoupler DNP, followed by reoxygenation
evoked by rapid removal of DNP, produced significant
Ca21 loading independently of gender (female: 729 6 88
nmol/liter, n 5 14; male: 778 6 97 nmol/liter, n 5 13, Fig.
1). The gender difference in the intracellular Ca21 concen-
tration was not statistically significant (p 5 0.110). How-
ever, the difference in the Ca21 concentration under control
conditions and following hypoxia-reoxygenation was statis-
tically significant (p , 0.001). No statistically significant
interaction existed between gender and cellular response to




Fluo-3AM 5 Fluo-3 acethoxymethyl ester
Figure 1. Hypoxia-reoxygenation induces Ca21 loading in both female and male cardiomyocytes. Time-course (left and central panels) of fluorescence in
Fluo-3 loaded female and male cardiomyocytes exposed to hypoxia-reoxygenation, with average concentrations of intracellular Ca21 prior and following
hypoxia-reoxygenation (right panel). Bars represent mean 6 SEM (n 5 13–14). Hypoxia-reoxygenation was induced by application (3 min at 37°C), and
removal of 2 mmol/liter DNP.
949JACC Vol. 36, No. 3, 2000 Jovanovic´ et al.
September 2000:948–52 17b-Estradiol and Direct Cytoprotection
17b-Estradiol prevents hypoxia-reoxygenation–induced
Ca21 loading in female, but not male, cardiomyocytes.
In female cardiac cells, pretreatment with 10 nmol/liter E2
significantly reduced the magnitude of hypoxia-
reoxygenation–induced Ca21 loading (untreated: 729 6 88
nmol/liter, n 5 14; E2-treated: 298 6 39 nmol/liter, n 5 7;
Figs. 1 and 2), without affecting the basal levels of Ca21 (see
Figs. 1 and 2). The difference between E2-treated and
untreated cells was statistically significant (p , 0.001). The
interaction between metabolic status of the cell and treat-
ment was also statistically significant (p , 0.001). This
effect was concentration-dependent, and at 1 nmol/liter E2
decreased Ca21 loading to 469 6 37 nmol/liter (n 5 14). In
contrast, in male cardiac cells pretreatment with E2 (10
nmol/liter) did not prevent hypoxia-reoxygenation–induced
Ca21 loading (untreated: 778 6 97 nmol/liter, n 5 13;
E2-treated: 1029 6 177 nmol/liter, n 5 6; Figs. 1 and 2).
The difference between E2-treated and untreated cells was
not statistically significant (p 5 0.308) and the interaction
between the metabolic status of a cell and treatment was also
not statistically significant (p 5 0.671). The gender-
dependent difference in response to the treatment with E2
was statistically significant (p , 0.001).
Tamoxifen blocks the protective action of E2. The pro-
tective effect of E2 (10 nmol/liter) was abolished by tamox-
ifen (1 mmol/liter), a partial agonist of estrogen receptors.
Following hypoxia-reoxygenation, in the presence of both
E2 (10 nmol/liter) and tamoxifen (1 mmol/liter), cytosolic
Ca21 levels increased to 702 6 98 nmol/liter in female
cardiomyocytes (n 5 5; E2-treated: 298 6 39 nmol/liter,
n 5 7, Fig. 3). The difference between E2-treated and
E21tamoxifen-treated cells was statistically significant (p 5
Figure 2. The 17b-estradiol (E2) prevents decreases hypoxia-reoxygenation–induced Ca21 loading in female, but not male, cardiomyocytes. Epifluorescent
digital images of Fluo-3AM loaded, and 10 nmol/liter pretreated cardiac cells from female (A) and male (B) hearts prior to and following
hypoxia-reoxygenation (H/R). Horizontal bar corresponds to 30 mm. Time-course of averaged Fluo-3 fluorescence in cells presented in A (A1) and B (B1).
AU: arbitrary units. (C) Average concentration of intracellular Ca21 at rest, and following hypoxia-reoxygenation. Bars represent mean 6 SEM (n 5 6–7).
Figure 3. Tamoxifen blocks the protective action of E2. Epifluorescent
digital images of Fluo-3AM loaded cardiac cells from female hearts,
pretreated with 10 nmol/liter E2 plus 1 mmol/liter tamoxifen, prior to and
following hypoxia-reoxygenation (H/R). Horizontal bar corresponds to
30 mm. (A1) Time-course of averaged Fluo-3 fluorescence in cell presented
in A. AU 5 arbitrary units. (B) Average concentration of intracellular
Ca21 at rest and following hypoxia-reoxygenation. Bars represent mean 6
SEM (n 5 5).
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0.002), and the interaction between the metabolic status of
a cell and treatment was also statistically significant (p ,
0.001).
17a-Estradiol does not prevent hypoxia-reoxygenation–
induced Ca21 loading in female cardiomyocytes. In fe-
male cardiac cells, pretreatment with 17a estradiol (10 nmol/
liter), an inactive estrogen stereoisomer, did not significantly
decrease the magnitude of hypoxia-reoxygenation–induced
Ca21 loading (17a estradiol-treated: 886 6 122 nmol/liter,
n 5 6; untreated: 729 6 88 nmol/liter, n 5 14, Fig. 4). The
difference between 17a estradiol-treated and untreated cells
was not statistically significant (p 5 0.107) and the inter-
action between the metabolic status of a cell and treatment
was also not statistically significant (p 5 0.852).
DISCUSSION
In the present study we demonstrate that physiological
levels of E2 confer resistance to female, but not male,
cardiomyocytes against intracellular Ca21 loading induced
by hypoxia-reoxygenation. These findings indicate that E2
is cytoprotective, and that gender is critical for E2 to exhibit
such a property.
In cardiomyocytes, reoxygenation that follows a hypoxic
insult initiates a series of cellular reactions (9,12). In
particular, hypoxia-reoxygenation induces intracellular
Ca21 loading, which represents a common denominator
leading to cell injury (9–11). In cardiomyocytes, used here,
basal levels of cytosolic Ca21 were low and similar to those
previously reported for healthy cells (8,9). The significant
increase in intracellular Ca21 following hypoxia-
reoxygenation confirms that cardiomyocytes are highly vul-
nerable to such an insult.
Female gender as a protector against ischemic heart
disease has been associated with high levels of circulating
estrogens (2,3). The beneficial effect of estrogens has been
traditionally ascribed to decrease in peripheral vascular
resistance and to an antiatherogenic action (3,13), although
more recently additional effects on the myocardium have
also been proposed (4–7). In the present study, exposure of
cardiomyocytes to nanomolar levels of E2 protected female,
but not male, cardiomyocytes against hypoxia-reoxygenation,
providing evidence at the cellular level for gender-
dependent cardioprotective properties of estrogens.
Our findings that exposure of cardiomyocytes to 17a-
estradiol, an inactive E2 stereoisomer, or to E2 in the
presence of the antiestrogen tamoxifen, did not protect
against hypoxia-reoxygenation further suggests that activa-
tion of estrogen receptors is necessary for the prevention of
Ca21 overload. In this regard, the present findings strongly
support previous studies, done at the whole heart level, that
have indicated a protective action of estrogens on the
myocardium itself (4–7). Moreover, the present study also
supports the notion that low blood levels of estrogens may
have direct cardioprotective properties in females (6). Using
single cardiomyocytes, a pure myocardial preparation free of
neuronal and vascular elements, we provide first direct
evidence that physiological levels of E2 indeed confer
resistance toward hypoxia-reoxygenation injury in a gender-
dependent manner.
In recent years, it has been reported that estrogen
supplementation may be beneficial in males under some
conditions of metabolic stress (14). Conversely, disruptive
mutation of the estrogen receptor gene in man has been
associated with premature coronary artery disease (15). The
present study indicates that gender difference in myocardial
response to metabolic insult is not solely the consequence of
different circulating E2 levels, but rather to a more profound
difference in the interaction between cardiomyocytes and
E2. In principle, estrogen receptors have been found in
cardiac cells in both males and females (16). However, it
should be mentioned that estrogen receptors are apparently
more functional and present at higher density in female than
in male cardiomyocytes, which may explain the gender-
dependence of E2-mediated cytoprotection observed in the
present study (17,18). In some studies, it has been demon-
strated that estrogens may be protective in a gender-
independent manner (4,5). Such findings have been ob-
tained by achieving higher blood levels of E2, which further
supports our conclusion that gender-dependent difference in
the response to low E2 concentration may be due to
differences in the density and function of estrogen receptors.
Taken together, it is apparent that activation of estrogen
receptors in a cardiac cell may protect this cell type against
metabolic stress, thus effectively preventing deleterious
Ca21 overload under hypoxia-reoxygenation injury.
Both the role and function of estrogen receptors in the
heart are still largely unknown. It is possible that E2 may
regulate the expression of genes that encode proteins impli-
cated in endogenous cardioprotection (19–21). In agree-
ment with such a possibility are recent findings that expres-
Figure 4. 17a Estradiol (E2) does not prevent hypoxia-reoxygenation–
induced Ca21 loading in female cardiomyocytes. Epifluorescent digital
images of Fluo-3AM loaded cardiac cells from female hearts pretreated
with 10 nmol/liter E2 prior to and following hypoxia-reoxygenation
(H/R). Horizontal bar corresponds to 30 mm. (A1) Time-course of
Fluo-3AM fluorescence in cell presented in A. AU: arbitrary units. (B)
Average concentration of intracellular Ca21 at rest and following hypoxia-
reoxygenation. Bars represent mean 6 SEM (n 5 6).
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sion of the cardiac calcium channel, an ion conductance
central in cardiac excitation-contraction coupling, is regu-
lated by activation of estrogen receptors (16). Moreover, it
has been recently demonstrated that estrogens up-regulate
the expression of protein kinase C, a signaling cascade
protein known to protect cardiomyocytes against Ca21
overload and associated cellular injury (22,23). Therefore, it
is possible that E2-induced expression of genes encoding
cytoprotective proteins protects cardiac cells against meta-
bolic stress.
Conclusion and significance. This study demonstrates,
for the first time, that E2 directly protects, in a gender-
dependent manner, cardiac cells against hypoxia-
reoxygenation injury through an estrogen receptor-
mediated mechanism. These findings may provide further
support for the therapeutic use of estrogens and contribute
to an understanding of the resistant phenotype associated
with female gender.
Study limitations. To determine the direct effect of E2 on
intracellular Ca21 concentration during hypoxia-
reoxygenation, it was necessary to image isolated cardiomy-
ocytes. Such approach provided a direct visualization of the
protective effect of E2 at the single-cell level. However, it
should be considered that, in intact myocardium, additional
cardiac, as well as extracardiac, mechanisms could further
modulate the action of E2.
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